CClinicalTrials.gg
CompletedNCT03284086Updated Sep 15, 2017

VO2peak and Exercise Efficiency in Upper-body Poling

An interventional study of upper-body double-poling and arm crank ergometry in Spinal Cord Injuries, sponsored by Norwegian University of Science and Technology. Completed at 1 site in Norway. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2017-09-15.

Sponsored by Norwegian University of Science and Technology · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This study compares peak oxygen uptake (VO2peak) and exercise efficiency in upper-body poling versus arm crank ergometry in trained able-bodied and paraplegic participants.

Read the detailed description

Peak oxygen uptake (VO2peak) and exercise efficiency are key factors for endurance performance. In persons who are primarily able to use their upper-body during exercise, such as many Paralympic athletes, the mode most commonly used in assessing VO2peak and efficiency is arm crank ergometry (ACE). However, sport-specificity of the test mode has been suggested to be of importance for achieving VO2peak and exercise efficiency that are reflective of the aerobic capacity in the respective sport. For ice sledge hockey players, cross-country sit skiers and sitting biathletes, upper-body poling (UP) is the most sport-specific test mode. However, it has not yet been investigated whether VO2peak and efficiency differ between ACE and UP. Therefore, the aim of this study was to compare VO2peak and exercise efficiency in upper-body poling versus arm crank ergometry in trained able-bodied and paraplegic participants. Participants performed four 5-min submaximal stages at increasing effort and an incremental peak test to exhaustion in both ACE and UP.

02

Conditions studied

  • Spinal Cord Injuries

Keywords

  • Oxygen consumption
  • Physical endurance
03

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • participants between the age of 18 and 50
  • well upper-body-trained participants with or without paraplegia

Exclusion criteria

Exclusion Criteria:

  • people with injuries or sicknesses that might have impacted the testing
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Other
    paraplegic

    Well-trained participants with a spinal cord injury (\<Th1) were included in this group.

    Diagnostic Test: upper-body double-poling · Diagnostic Test: arm crank ergometry

  • Other
    able bodied

    Upper-body trained, able-bodied participants were included in this group.

    Diagnostic Test: upper-body double-poling · Diagnostic Test: arm crank ergometry

Interventions

  • Diagnostic testupper-body double-poling

    An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the upper-body double-poling mode.

  • Diagnostic testarm crank ergometry

    An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the arm crank ergometry mode.

05

What researchers measure

Primary outcomes

  1. Peak oxygen uptake

    Peak oxygen uptake was measured during an incremental test to exhaustion.

    Time frame: 3 weeks

06

Study locations

1 site
  • Centre for Elite Sports Research
    Trondheim, Norway
07

References and documents

Individual participant data

Plan to share: Yes — All data will be de-identified by the project coordinator. The de-identified data will be stored on the NTNU server in a folder that only the JKB and ØS have access to. For analysing the data, parts of the de-identified data might be distributed amongst the four researchers and two master students linked to this study.

Supporting information: Study protocol, Sap, Icf

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03284086
Lead sponsor
Norwegian University of Science and Technology
Collaborators
St. Olavs Hospital
Responsible party
Sponsor
First posted
Sep 15, 2017
Start date
Sep 2016
Primary completion
May 2017
Completion
May 2017
Last update
Sep 15, 2017

Study contacts

Jorunn Helbostad, phd prof
study director · Dept of Neuromedicine and Movement Science, Norwegian University of Science and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion